A
7AY1
vs
D
DAX Index
Over the past 12 months, 7AY1 has underperformed DAX Index, delivering a return of -12% compared to the DAX Index's +9% growth.
Stocks Performance
7AY1 vs DAX Index
Performance Gap
7AY1 vs DAX Index
Performance By Year
7AY1 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Actinium Pharmaceuticals Inc
Glance View
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The firm develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).
